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Abstract 
Background: Venous thromboembolism (VTE) is a significant source of mortality, morbidity, 
disability, and impaired health-related quality of life in the world.  
Objective: We aimed to evaluate the clustering patterns and associations of 29 comorbidities 
with in-hospital death among adult hospitalizations with a diagnosis of VTE in the United States by 
analyzing data from the 2009 Nationwide Inpatient Sample.  
Methods: This cross-sectional study included 153,124 adult hospitalizations with a diagnosis of 
VTE. Adjusted rate ratios and 95% confidence intervals (CI) for in-hospital death were generated 
by using multivariable log-linear regression models to measure independent associations between 
comorbidities and in-hospital death.  
Results: We estimated that 44,200 in-hospital deaths occurred in 2009 among 773,273 US adult 
hospitalizations with a diagnosis of VTE. Subgroups of hospitalizations with comorbidities of 
“congestive heart failure,” “chronic pulmonary disease,” “coagulopathy,” “liver disease,” “lym-
phoma,” “fluid and electrolyte disorders,” “metastatic cancer,” “peripheral vascular disorders,” 
“pulmonary circulation disorders,” “renal failure,” “solid tumor without metastasis,” or “weight 
loss” were positively and independently associated with 1.07 (95% CI: 1.02−1.12 ) to 2.06 (95% CI: 
1.97−2.16) times increased likelihoods of in-hospital death, when compared to those without the 
corresponding comorbidities. The clustering patterns of these comorbidities by 4 disease cate-
gories (i.e., “cancer,” “cardiovascular/respiratory/blood,” “gastrointestinal/urologic,” and “nutri-
tional/bodyweight”) were associated with 2.74 to 10.28 times increased likelihoods of in-hospital 
death, as compared to hospitalizations without any of these comorbidities. The overall increase in 
the cumulative number of comorbidities corresponded to significantly elevated risks 
(P-trend<0.01) for in-hospital death among hospitalizations with a diagnosis of VTE.  
Conclusion: The presence of multiple comorbidities is ubiquitous among hospitalizations of 
adults with VTE and among in-hospital deaths with VTE in the United States. The findings of our 
study further suggest that, among hospitalizations of adults with VTE, the presence of certain 
comorbidities or clustering of these comorbidities significantly elevates the risk of in-hospital 
death. 
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Venous thromboembolism (VTE), presenting 
clinically as pulmonary embolism or deep vein 
thrombosis, and its long-term sequelae of 
post-thrombotic syndrome and chronic thromboem-
bolic pulmonary hypertension are significant sources 
of mortality, morbidity, disability, and impaired 
health-related quality of life in the world [1-4]. From 
the classic Virchow’s triad (i.e., vascular endothelial 
damage, stasis of blood flow, and hypercoagulability 
of blood) to the current classification scheme of un-
provoked (e.g., idiopathic) and provoked (e.g., sec-
ondary) VTE resulting from transient (e.g., fractures) 
or persistent risk factors (e.g., cancer) [5-7], research 
over the past several decades has unveiled that VTE is 
a multifaceted disease affecting individuals across 
various socio-demographic groups [4, 7, 8]. 
A previous study reported that, among patients 
with a confirmed episode of VTE, about 74% devel-
oped VTE in the outpatient setting and 37% of such 
outpatients had a recent hospitalization in the pre-
ceding 3 months [9]. Recent data from the National 
Hospital Discharge Survey linked VTE to more than 
half a million US adult hospitalizations annually 
during 2007−2009 [10]. The risk of VTE and its prog-
nostic health consequences increase with age and are 
associated with comorbidity—the presence of addi-
tional disease in relation to an index disease such as 
VTE [4, 11-14]. Advances in healthcare research 
demonstrate that comorbidities can affect one or more 
diseases through the etiological mechanisms of direct 
causation (e.g., disease A is directly responsible for 
disease B), associated risk factors (e.g., correlated risk 
factors make concurrent diseases more likely to oc-
cur), heterogeneity (e.g., independent risk factors for 
either disease), and independence (e.g., some diag-
nostic features of the co-occurring diseases actually 
correspond to a third distinct disease) [11]. An in-
creasing body of research shows that comorbidities 
may confound clinical assessment [15, 16], hinder 
timely diagnosis [17], and aggravate complications 
and recurrence [18-21], thereby placing patients with 
VTE at heightened risks for many debilitating health 
consequences including death [19].  
To date, numerous studies have identified a 
myriad of biological, behavioral, health, and envi-
ronmental risk factors that are independently associ-
ated with risk of developing VTE [4-8]. Yet, limited 
research has been conducted to evaluate the joint 
impact of VTE and various medical illnesses on mor-
tality in hospitalized patients with VTE. To the best of 
our knowledge, no study has evaluated the pattern 
and concurrent impacts of comorbidities on 
in-hospital death among US adult hospitalizations 
with VTE. Therefore, this study aimed to evaluate the 
clustering patterns and associations of comorbidities 
with in-hospital death among adult hospitalizations 
with a diagnosis of VTE in the United States by ana-
lyzing data from the 2009 Nationwide Inpatient Sam-
ple (NIS). 
Materials and methods 
Data Source 
The NIS is part of the Healthcare Cost and Uti-
lization Project sponsored by the Agency for 
Healthcare Research and Quality (AHRQ). It is the 
largest all-payer inpatient care database and includes 
5−8 million annual unweighted hospitalizations of 
patients covered by Medicare, Medicaid, private in-
surance, and the uninsured from about 1,000 com-
munity hospitals in the United States. The NIS is de-
signed to approximate a 20% sample of US commu-
nity hospitals; all hospitalizations from sampled hos-
pitals are included in the NIS [22]. The NIS sampling 
frame consists of non-federal, short-term, general, 
specialty hospitals, and long-term acute care facilities. 
Excluded from the NIS are short-term rehabilitation 
hospitals, long-term non-acute care hospitals, psychi-
atric hospitals, and alcoholism/chemical dependency 
treatment facilities [22]. Details about the sampling 
methodology are described elsewhere [23]. All sam-
pling procedures involving human subjects and con-
fidentiality were reviewed and approved by the Re-
search Ethics Review Board of the AHRQ [23]. The 
2009 Inpatient Core file contains data for 7,810,762 
hospitalizations drawn from 1,050 hospitals of par-
ticipating states that comprise 96% of the US popula-
tion.  
Inpatient Sample 
Each sampled hospitalization in the NIS includes 
a maximum of 25 diagnostic codes based on the In-
ternational Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM). VTE was identified 
using ICD-9-CM codes 415.1x, 451.1x, 451.2, 451.8x, 
451.9, 453.2, 453.4x, 453.8x, and 453.9 in any of the 
diagnostic fields. We limited our analysis to an un-
weighted sample of hospitalizations for adults aged 
18 years and older with a diagnosis of VTE 
(n=154,047). We excluded hospitalizations related to 
pregnancy, childbirth, and puerperium of patients 
who are mostly young, who have a low incidence of 
comorbidities and VTE, and who have a small risk of 
death during hospitalization, although the risk of 
developing VTE may be increased during pregnancy 
and postpartum period [24-27]. After excluding hos-
pitalizations due to pregnancy, childbirth, and puer-
perium and variables with missing information for 




sex, vital status, length of hospital stay, or status of 
primary expected payer, 153,124 unweighted hospi-
talizations were included in the analyses.  
Demographic, Clinical, and Insurance Char-
acteristics 
The demographic variables included age, sex, 
and race/ethnicity (15% missing data). Because of 
potential misclassification and some participating 
states do not report race/ethnicity information, na-
tional estimates for race/ethnicity should be inter-
preted with caution. In addition, we included clinical 
characteristics and insurance status (i.e., days of hos-
pital stay, insurance status of primary expected payer, 
and status of operating room procedure) as covari-
ates, because of their relevance to the outcome and 
prevention of VTE. The NIS assigns all ICD-9-CM 
procedure codes to 4 broad categories of minor diag-
nostic, minor therapeutic, major diagnostic, and major 
therapeutic according to the AHRQ Procedure Classes 
[28]. An operating room procedure is defined in the 
NIS as having at least one major diagnostic or major 
therapeutic procedure during hospitalization [29].  
Comorbidity 
Comorbidities are considered in the NIS as co-
existing medical conditions that are not directly re-
lated to the principal diagnosis or the main reason for 
admission, and are likely to have originated prior to 
the hospital stay [30]. Charlson et al and Elixhauser et 
al developed two well-known comorbidity indices for 
risk adjustment in health outcomes research [24, 25]. 
Lately, the Elixhauser comorbidity index has been 
found superior for risk adjustment and has been in-
creasingly used in administrative datasets [31-34]. 
While the original Elixhauser comorbidity index con-
tained 30 comorbidities based on ICD-9-CM coding 
algorithms for diagnoses and diagnosis-related group, 
the NIS included 29-comorbidity variables excluding 
“cardiac arrhythmias” [25, 30]. We constructed an 
ordinal variable to indicate the total number of AHRQ 
comorbidities for each hospitalization and catego-
rized the variable into groups with 1, 2, 3, 4, 5 or more 
comorbidities.  
Statistical Analysis 
We calculated the percentage distribution and 
case-fatality rates of adult hospitalizations with a di-
agnosis of VTE stratified by age, sex, race/ethnicity, 
days of hospital stay, insurance status of primary ex-
pected payer, operating room procedure, and number 
of comorbidities. Regardless of actual causes of death, 
we defined the case-fatality rate in this study as the 
percentage of hospitalizations of patients with a VTE 
diagnosis who died during the study period [35]. We 
estimated the number of deaths with a diagnosis of 
VTE overall in 2009 and by number of comorbidities. 
We calculated the prevalence of each of the 29 
comorbidities among adult hospitalizations. To iden-
tify comorbidities that were independently associated 
with in-hospital death in the study sample, we em-
ployed a backward elimination procedure to remove 
any explanatory variable with the highest P ≥ 0.05 for 
individual t-test of null hypothesis β=0. The same 
procedure was repeated until P < 0.05 for all explan-
atory variables remaining in the final model. Adjusted 
rate ratios (aRRs) and 95% confidence intervals (CI) 
for in-hospital death were generated by using multi-
variate log-linear regression models to measure in-
dependent associations between remaining comor-
bidities and in-hospital death while controlling for 
age, sex, race/ethnicity, days of hospital stay, primary 
expected payer, and status of operating room proce-
dure. We calculated the rate ratios for in-hospital 
death by number of comorbidities and by cumulative 
severity scores among adult hospitalizations with 
VTE. We assessed the distribution of 16 clustering 
patterns for 12 comorbidities by 4 disease categories 
(i.e., “cancer,” “cardiovascular/respiratory/blood,” 
“gastrointestinal/urologic,” and “nutritional/ 
bodyweight”) and calculated adjusted rate ratios 
(aRRs) for in-hospital death among adult hospitaliza-
tions with a diagnosis of VTE. We performed or-
thogonal polynomial contrasts to test linear and 
quadratic trends to indicate the increase or decrease of 
aRRs across the categories of comorbidity while con-
trolling for covariates. We performed the data man-
agement and analysis using SPSS 18 Complex Sam-
ples for Survey Analysis (IBM Corp) and STATA 11 
(StataCorp LP) to account for multiple stages of sam-
pling, weighting, stratification, and clustering. All 
estimates in this study were weighted unless other-
wise noted as unweighted sample size (n). 
Results 
We estimated that 44,200 in-hospital deaths oc-
curred in 2009 among adult hospitalizations with a 
diagnosis of VTE in the United States, representing an 
overall case-fatality rate of 5.7%. Approximately 
97.9% of these deaths had at least 1 comorbidity (Fig-
ure 1). The case-fatality rates varied significantly by 
age, sex, race/ethnicity, days of hospital stay, insur-
ance status of primary expected payer, status of op-
erating room procedure, and the number of comor-
bidities (P< 0.001) (Table 1). For instance, large per-
centages of hospitalizations with VTE were observed 
among subgroups for patients who were 50-79 years 
of age, female, white, less than 7 days of hospital stay, 
or with “no procedure of any kind.” However, high 
case-fatality rates were observed among subgroups 




with 80 years and older, male, Asian or other 
race/ethnicity, or “non-operating room procedure.” 
Additionally, the case-fatality rates were higher 
among subgroups of patients whose primary ex-
pected payer was Medicare or who had at least 5 
comorbidities than among those with other insurance 
payers or with fewer number of comorbidities (P< 
0.001) (Table 1).  
Of 29 comorbidities from the AHRQ comorbidity 
index, 12 comorbidities were significantly and posi-
tively associated with in-hospital death among hos-
pitalizations with VTE, after adjustment of covariates 
including age, sex, race/ethnicity, days of hospital 
stay, primary expected payer, status of operating 
room procedure, and remaining comorbidities (Table 
2). For example, when compared to subgroups with-
out corresponding comorbidity, subgroups with 
comorbidity of “congestive heart failure,” “chronic 
pulmonary disease,” “coagulopathy,” “liver disease,” 
“lymphoma,” “fluid and electrolyte disorders,” 
“metastatic cancer,” “peripheral vascular disorders,” 
“pulmonary circulation disorders,” “renal failure,” 
“solid tumor without metastasis,” and “weight loss” 
were each independently associated with 1.07 to 2.06 
times increased likelihoods of in-hospital death. The 
prevalence for having any one of 12 comorbidities 
ranged from 1.6% for “lymphoma” to 28.3% for “fluid 
and electrolyte disorders,” whereas the case-fatality 
rates fluctuated between 6.8% for “chronic pulmonary 
disease” and 13.6% for “coagulopathy” (Table 2). 
Furthermore, the increase in cumulative number of 
comorbidities generally corresponded to significantly 
elevated risks of in-hospital death among hospitaliza-
tions with VTE (P-trend<0.01) (Figure 2). The detec-
tion of a significant quadratic trend with an accom-
panying linear trend (P<0.001) signaled the presence 
of nonlinear variation (e.g., trend flattened out or lev-
eled off) along with an overall linear trend (Figure 2). 
The disease category of “cardiovascular/blood/ 
respiratory,” either by itself (21.8%) or combined with 
the disease categories for other comorbidities (27.6%) 
(i.e., “cancer,” “gastrointestinal/renal,” and “nutri-
tional/body weight”), was most prevalent and ac-
counted for nearly half (49.4%) of adult hospitaliza-
tions with VTE. The clustering patterns of 12 comor-
bidities by 4 disease categories were associated with 
2.74 to 10.28 times increased likelihoods of in-hospital 
death, as compared to adult hospitalizations without 
any of the 12 comorbidities (Table 3). Regardless, 
28.9% adult hospitalizations with VTE did not have 
any of the 12 comorbidities of concern.  
 
 
Figure 1. Percentage distribution of estimated number of in-hospital deaths with VTE by status of comorbidity, NIS, 2009 





Figure 2. Adjusted rate ratios for in-hospital death by number of comorbidities among US adult hospitalizations with VTE, NIS, 2009 
 
Table 1. Percentage distribution and case-fatality rates of adult hospitalizations with a diagnosis of VTE by demographic and clinical 
characteristics, NIS, 2009 
Characteristics Unweighted 
n 
Estimated distribution In-hospital death (Na = 44,200) 
N % Case-fatality (%) CIb P-valuec 
Overall 153,124 773,273 100 5.7 5.5−5.9  
Age      P<0.001 
 18−49 32,448 163,007 21.1 2.7 2.5−3.0  
 50−79 87,401 441,227 57.1 6.0 5.7−6.2  
 ≥80 33,275 169,039 21.9 7.9 7.5−8.3  
Sex      P<0.001 
 Male 73,324 369,954 47.9 6.0 5.8−6.3  
 Female 79,800 403,319 52.1 5.4 5.2−5.7  
Race/ethnicityd      P<0.001 
 White 93,654 473,796 61.3 5.6 5.4−5.9  
 Black 20,814 105,294 13.6 5.8 5.4−6.2  
 Hispanic 9,074 45,842 5.9 6.1 5.6−6.8  
 Asian or other race/ethnicity 6,289 32,321 4.2 7.8 7.0−8.6  
 Not stated 23,293 116,020 15.0 5.3 4.7−6.0  
Days of hospital stay      P<0.001 
 < 7 days 83,673 422,955 54.7 4.3 4.1−4.5  
 ≥ 7 days  69,451 350,318 45.3 7.5 7.2−7.8  
Primary expected payer      P<0.001 
 Medicare 85,207 431,696 55.8 6.7 6.4−6.9  
 Medicaid 13,829 69,660 9.0 4.8 4.4−5.2  
 Private including HMO 42,151 212,229 27.4 4.5 4.2−4.8  
 Self-pay or other payers 11,937 59,688 7.7 4.4 4.0−4.9  
Operating room procedure      P<0.001 
 No procedure of any kind recorded 61,111 309,521 40.0 1.9 1.8−2.1  
 Non-operating room procedure 
 recordede 
48,877 246,454 31.9 9.5 9.1−9.9  
 Operating room procedure recordedf 43,136 217,298 28.1 6.6 6.3−6.9  
Number of comorbiditiesg      P<0.001 
 0 10,998 55,743 7.2 1.7 1.4−2.0  
 1 23,177 117,449 15.2 3.4 3.1−3.7  
 2 30,808 156,034 20.2 4.4 4.1−4.8  
 3 30,831 154,254 19.9 5.3 5.5−5.7  
 4 24,205 122,067 15.8 6.4 6.0−6.8  
 ≥5 33,405 167,726 21.7 9.7 9.3−10.2  
a. Estimated (N) number of in-hospital deaths with a diagnosis of VTE. b. 95% confidence interval. c. P-value for Pearson Chi-Square test. d. May not be nationally representative because 
not all participating states collect race/ethnicity information. e. Had at least one minor diagnostic or minor therapeutic procedure (without any major diagnostic or major therapeutic 
procedure) during hospitalization. f. Had at least one major diagnostic or major therapeutic procedure during hospitalization. g. Based on AHRQ 29-comorbidity index. 




Table 2. Prevalence of comorbidity, case-fatality rates and rate ratios for in-hospital death among adult hospitalizations with a diagnosis 
of VTE, NIS, 2009 







Association with in-hospital death 
% 95% CIc Case-fatality rate 95% CI Adjusted RRd 95% CI 
Acquired immune deficiency syndrome 549 2,756 0.4 0.3−0.4 3.7 2.3−5.9 −e − 
Alcohol abuse 4,868 24,442 3.2 3.0−3.3 4.7 4.2−5.3 0.84 0.74−0.95 
Anemia (deficiency) 38,261 192,405 24.9 23.9−25.8 5.9 5.6−6.3 0.72 0.68−0.76 
Arthritis (rheumatoid)/collagen vascular 
diseases 
5,209 26,254 3.4 3.3−3.5 4.9 4.4−5.6 − − 
Chronic blood loss anemia 2,904 14,636 1.9 1.8−2.0 5.6 4.8−6.6 0.66 0.57−0.77 
Congestive heart failuref 19,627 99,176 12.8 12.4−13.3 10.8 10.3−11.4 1.43 1.36−1.50 
Chronic pulmonary disease 32,301 163,376 21.1 20.5−21.7 6.8 6.4−7.2 1.07 1.02−1.12 
Coagulopathy 12,685 63,524 8.2 7.8−8.6 13.6 12.8−14.4 1.84 1.74−1.94 
Depression 15,878 80,027 10.3 10.0−10.7 3.6 3.3−4.0 0.72 0.67−0.79 
Diabetes, uncomplicated 29,750 150,104 19.4 19.0−19.9 5.6 5.3−6.0 − − 
Diabetes with chronic complications 6,936 34,879 4.5 4.3−4.8 5.5 4.9−6.1 0.83 0.75−0.92 
Drug abuse 3,806 19,116 2.5 2.3−2.7 3.3 2.8−4.0 0.80 0.67−0.95 
Hypertension (uncomplicated and com-
plicated) 
82,484 416,519 53.9 53.0−54.7 5.0 4.7−5.2 0.70 0.66−0.73 
Hypothyroidism 16,938 85,473 11.1 10.7−11.4 5.0 4.6−5.4 0.88 0.82−0.94 
Liver disease 3,722 18,665 2.4 2.3−2.6 7.9 7.0−8.9 1.17 1.04−1.32 
Lymphoma 2,512 12,719 1.6 1.5−1.8 9.4 8.3−10.7 1.43 1.27−1.62 
Fluid and electrolyte disorders 43,505 218,526 28.3 27.4−29.1 10.8 10.4−11.2 1.90 1.82−1.98 
Metastatic cancer 10,949 55,362 7.2 6.9−7.5 11.4 10.7−12.1 1.89 1.77−2.01 
Other neurological disorders 14,270 72,079 9.3 9.1−9.6 6.2 5.8−6.7 − − 
Obesity 18,744 94,178 12.2 11.7−12.7 3.8 3.5−4.1 0.86 0.79−0.93 
Paralysis 6,356 31,978 4.1 3.9−4.4 6.9 6.2−7.6 1.10 1.00−1.21 
Peripheral vascular disorders 9,322 46,873 6.1 5.8−6.3 8.3 7.7−8.9 1.21 1.13−1.30 
Psychoses 6,390 32,150 4.2 4.0−4.4 4.1 3.6−4.7 0.79 0.70−0.90 
Pulmonary circulation disorders 30,267 152,273 19.7 19.2−20.2 11.0 10.5−11.5 2.06 1.97−2.16 
Renal failure 23,036 116,090 15.0 14.5−15.6 8.2 7.8−8.7 1.38 1.30−1.45 
Solid tumor without metastasis 7,487 37,893 4.9 4.7−5.1 7.6 6.9−8.2 1.34 1.23−1.47 
Peptic ulcer disease excluding bleeding 73 371 0 0−0.1 − − − − 
Valvular disease 6,804 34,318 4.4 4.2−4.7 7.5 6.8−8.3 0.86 0.79−0.94 
Weight loss 14,080 70,584 9.1 8.6−9.7 13.1 12.4−13.8 1.39 1.32−1.47 
a. Referent groups were adult hospitalizations without corresponding comorbidity (suppressed). b. Subgroup with comorbidity are shown (subgroups without comorbidity: n = 153,124 - n 
for subgroup with corresponding comorbidity). c. 95% confidence interval. d. Rate ratios from log-linear regression model with backward elimination procedure that adjusted for age 
(continuous), sex, race/ethnicity, days of hospital stay (continuous), primary expected payer, major operating room procedure, and all comorbidities excluding “acquired immune defi-
ciency syndrome,” “arthritis (rheumatoid)/collagen vascular diseases,” “diabetes uncomplicated,” “Other neurological disorders,” and “peptic ulcer disease excluding bleeding.” e. 
Variable not in the final regression model. f. Comorbidities significantly and positively associated with in-hospital death are bolded. 
Table 3. Distribution of clustering patterns for 12 comorbidities by disease category and rate ratios for in-hospital death among adult 
hospitalizations with a diagnosis of VTE, NIS, 2009 













 Clustering pattern  N % aRRe CI 
4  +f + + + 740 3,730 0.5 10.28 8.66−12.20 
3 + + + -g 667 3,380 0.4 6.38 4.97−8.19 
3 - + + + 6,441 32,299 4.2 7.85 7.00−8.79 
3 + - + + 453 2,282 0.3 6.86 5.40−8.72 
3 + + - + 3,795 19,138 2.5 8.45 7.51−9.50 
2 + + - - 5,201 26,313 3.4 5.00 4.42−5.67 
2 - + + - 7,344 37,045 4.8 3.73 3.29−4.24 
2 - - + + 3,707 18,677 2.4 4.41 3.81−5.11 
2 + - + - 652 3,302 0.4 3.12 2.23−4.38 
2 + - - + 3,091 15,626 2.0 5.44 4.71−6.27 
2 - + - + 17,815 89,284 11.5 6.10 5.48−6.80 
1 + - - - 6,203 31,452 4.1 2.46 2.11−2.86 
1 - + - - 33,267 168,271 21.8 2.74 2.48−3.03 
1 - - + - 6,032 30,422 3.9 1.65 1.35−2.01 
1 - - - + 13,715 68,954 8.9 2.98 2.66−3.34 
0 - - - - 44,001 223,098 28.9 1.00 Referenceh 
Total number of hospitalizations 153,124 773,273 100.0 − − 




a. Presence of one or more comorbidities of lymphoma, metastatic cancer, and solid tumor without metastasis. b. Presence of one or more comorbidities of congestive heart failure, chronic 
pulmonary disease, coagulopathy, peripheral vascular disorders, and pulmonary circulation disorders. c. Presence of one or more comorbidities of liver disease and renal failure. d. 
Presence of one or more comorbidities of fluid and electrolyte disorders and weight loss. e. Rate ratios from log-linear regression model that adjusted for age, sex, race/ethnicity, days of 
hospital stay, primary expected payer, major operating room procedure, and comorbidities retained without 12 comorbidities. f. Presence of one or more comorbidities of the disease 
category. g. Absence of any comorbidity of the disease category. h. Absence of 12 comorbidities. 
 
Discussion 
By using a large nationally representative sam-
ple, our study evaluated the AHRQ 29-comorbidity 
index encompassing the clustering patterns and asso-
ciations with in-hospital death among US adult hos-
pitalizations with a diagnosis of VTE that have not 
been reported in the past. Of US adult hospitalizations 
with VTE, about 9 in 10 had at least 1 comorbidity and 
1 in 3 had at least 4 comorbidities. A vast majority of 
in-hospital deaths with VTE had at least 1 comorbid-
ity. From the well-recognized “metastatic cancer 
(aRR=1.89; CI: 1.77−2.01)” to the less pronounced 
“fluid and electrolyte disorders (aRR=1.90; CI: 
1.82−1.98),” we identified 12 of these 29 comorbidities 
that were significantly associated with the risk of 
in-hospital deaths. In addition, increases in the cu-
mulative number of comorbidities were associated 
with significantly elevated risks of in-hospital death 
among those hospitalizations.  
The findings of our study have several important 
implications for clinical and public health research, 
practice, and planning. First, the ubiquitous presence 
of co-morbidities among patients with VTE suggests 
that, to a great extent, VTE is an important marker or 
reminder for the co-existence of other diseases or 
conditions. For instance, VTE may reflect the presence 
of a biologically more aggressive cancer in an early 
stage [14]. Therefore, healthcare practitioners must 
remain vigilant in evaluating patients with VTE, par-
ticularly those who may have clustering comorbidi-
ties that may predispose them to a heightened risk for 
death. Second, the breadth of co-morbidities among 
hospitalizations of patients with VTE demonstrates 
the complexity of potential disease-interacting 
mechanisms of (a) direct causation (e.g., cancer may 
compress adjacent veins to limit blood flow and pro-
duce procoagulant proteins and inflammatory cyto-
kines that contribute to hypercoagulability) [36, 37], 
(b) associated risk factors (e.g., VTE and congestive 
heart failure may co-occur because inflammation and 
coronary heart disease are correlated risk factors, re-
spectively) [38-40], (c) heterogeneity (e.g., aging and 
trauma are independent risk factors for either VTE or 
fluid and electrolyte disorders) [41, 42], and (d) inde-
pendence (e.g., concurrent weight loss and renal fail-
ure resulting from cancer) [43]. As such, comorbidities 
not only have value in diagnostic and prognostic as-
sessment of patients with VTE [11, 44, 45], but can also 
affect quality of patient care (e.g., adherence to clinical 
guidelines) [46, 47]. Third, we observed that almost 
half (49.4%) of adult hospitalizations with VTE also 
had at least one comorbidity in the “cardiovascu-
lar/blood/respiratory” disease category. Research 
suggests that concordant comorbidities are those dis-
eases that may share overlapping pathophysiologic 
risk factors, thus benefit from similar disease man-
agement strategies and may result in improved qual-
ity of patient care [48, 49]. For example, arterial 
thrombosis and VTE are two distinct forms of 
thrombosis with interrelated risk factors [50]. The 
JUPITER study reported that the use of statins re-
sulted in a 43% reduction of VTE events in apparently 
healthy adults aged 50 years and older with high lev-
els of C-reactive protein (≥2mg/L) and normal levels 
of low-density lipoprotein cholesterol [51]. In contrast, 
discordant comorbidities are not directly related in 
either pathogenesis or management of relevant dis-
eases. Because of the additional implementation bur-
den from multiple clinical recommendations or prac-
tice guidelines, competing demands for physician 
attention, and elevated risks of adverse drug events or 
complications, discordant comorbidities may lead to 
reduced quality of patient care [48, 49]. Hence, sub-
stantial work remains for practitioners and research-
ers to elucidate the role of interacting VTE and 
comorbidities, to prioritize care of complex patients, 
and to inform prevention programs. 
Based on the ascertainment of up to 25 diagnos-
tic codes for each hospitalization in the NIS sample, a 
total of 44,200 in-hospital deaths were approximated 
among adult hospitalizations with VTE in 2009. Sim-
ilar to the findings of our study, the 12 comorbidities 
overlapped with some comorbidities that were pre-
viously found to be associated with increased risks for 
in-hospital death in studies using a non-VTE-specific 
overall sample [31, 52]. Possibly as a surrogate for 
relatively “healthy” patients when compared to those 
with more serious diseases, the presence of the 11 
non-life-threatening comorbidities in our study was 
associated with decreased risks of in-hospital death 
(Table 2). Although the reason remained unclear for 
the lower case-fatality rate in hospitalization with 
“operating room procedure” than that of 
“non-operating room procedure,” additional research 
discerning these risk factors is needed in order to 
identify potential diagnostic and therapeutic proce-
dures (e.g., venous catheterization) and associated 
conditions that may contribute to an elevated risk of 
death.  
Our study has several limitations. We were una-
ble to determine any causal inference because the 




cross-sectional study design cannot establish such a 
relationship. Due to the constraints of administrative 
datasets, we were unable to control for potential 
medications that may otherwise affect short-term 
mortality in patients with VTE. Even though ICD-9 
codes provide a uniform identification of comorbidi-
ties in administrative datasets, the accuracy of diag-
nostic codes may vary by physician documentations, 
code assignments, usage patterns for diagnostic tests, 
changes of codes over time, and institutional reim-
bursement policies [53].  
More than 66% of all healthcare costs or 96% of 
Medicare expenditures are for individuals with two or 
more chronic diseases and conditions [54, 55]. Also, 
given that comorbidities are highly prevalent among 
aging US adults and are associated with worse health 
outcomes and more complex clinical management, 
effectively addressing multiple chronic diseases and 
conditions poses a complex set of challenges for clini-
cians, patients, and healthcare systems [54-56]. More 
results from intervention studies that can demonstrate 
efficacy and safety in the presence of co-occurring 
diseases are beneficial.  
Conclusion 
 The presence of multiple comorbidities is ubiq-
uitous among hospitalizations of adults with VTE and 
among in-hospital deaths with VTE in the United 
States. The findings of our study further suggest that, 
among hospitalizations of adults with VTE, the pres-
ence of certain comorbidities or clustering of these 
comorbidities significantly elevates the risk of 
in-hospital death. 
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